Market Research Logo

Global Lung Cancer Liquid Biopsy Market 2017-2021

Global Lung Cancer Liquid Biopsy Market 2017-2021

About Lung Cancer Liquid Biopsy

A liquid biopsy helps to identify free-floating tumor DNA (also known as circulating DNA) within the blood sample of a patient. Lung cancer liquid biopsy helps to detect the epidermal growth factor receptor (EGFR) mutation and other identified mutations, which are responsible for lung cancer. It is observed that the use of a liquid biopsy to identify carcinogenic cells of lungs will help in the early diagnosis of lung cancer.

Technavio’s analysts forecast the global lung cancer liquid biopsy market to grow at a CAGR of 17.15% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global lung cancer liquid biopsy market for 2017-2021. To calculate the market size, the report considers the sales and values of lung cancer liquid biopsy assays.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA
Technavio's report, Global Lung Cancer Liquid Biopsy Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • Biocept
  • Exosome Diagnostics
  • F. Hoffmann-La Roche
  • QIAGEN
Other prominent vendors
  • AccuraGen
  • Agena Bioscience
  • BARD1
  • BGI
  • Biodesix
  • Bio-Rad Laboratories
  • Cancer Genetics
  • CellMax Life
  • Circulogene
  • CLEARBRIDGE BIOMEDICS
  • Cynvenio Biosystems
  • EntroGen
  • Epic Sciences
  • Epigenomics
  • Fluxion Biosciences
  • Freenome
  • Gencurix
  • Genetracer Biotech
  • Genomic Health
  • Grail
  • Guardant Health
  • HeliTec
  • Inivata
  • Lonza
  • MedGenome
  • Nanoview Diagnostics
  • Natera
  • Novogene
  • OncoCyte
  • OncoDNA
  • Pathway Genomics
  • Personal Genome Diagnostics
  • Predicine
  • Shuwen Biotech
  • Sysmex
  • Thermo Fisher Scientific
  • Transgenomic
  • Trovagene
Market driver
  • Rising incidence of lung cancer
  • For a full, detailed list, view our report
Market challenge
  • High cost of lab testing procedure
  • For a full, detailed list, view our report
Market trend
  • Vendors' focus on clinical trials
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?


Press Release

Technavio Announces the Publication of its Research Report – Global Lung Cancer Liquid Biopsy Market 2017-2021

Technavio recognizes the following companies as the key players in the global lung cancer liquid biopsy market: Biocept, Exosome Diagnostics, F. Hoffmann-La Roche, and QIAGEN

Other Prominent Vendors in the market are: AccuraGen, Agena Bioscience, BARD1, BGI, Biodesix, Bio-Rad Laboratories, Cancer Genetics, CellMax Life, Circulogene, CLEARBRIDGE BIOMEDICS, Cynvenio Biosystems, EntroGen, Epic Sciences, Epigenomics, Fluxion Biosciences, Freenome, Gencurix, Genetracer Biotech, Genomic Health, Grail, Guardant Health, HeliTec, Inivata, Lonza, MedGenome, Nanoview Diagnostics, Natera, Novogene, OncoCyte, OncoDNA, Pathway Genomics, Personal Genome Diagnostics, Predicine, Shuwen Biotech, Sysmex, Thermo Fisher Scientific, Transgenomic, and Trovagene.

Commenting on the report, an analyst from Technavio’s team said: “The latest trend gaining momentum in the market is Vendors' focus on clinical trials. The global lung cancer liquid biopsy market is in its growth stage, which offers a great platform for manufacturers to investigate on products through clinical trials. The increasing funding by big investors such as Amazon, GV, and Johnson and Johnson provides an opportunity for new entrants to penetrate the market with their novel products.”

According to the report, one of the major drivers for this market is Rising incidence of lung cancer. Lung cancer is regarded as one of the highest causes of cancer deaths globally. The two types of lung cancers, which grow and spread differently, are SCLC and NSCLC. The major risk factors for the increased lung cancer are (tobacco) smoking and factors such as asbestosis, air pollution, passive smoking, and abnormalities observed in genes (changes in gene base pairing).

Further, the report states that one of the major factors hindering the growth of this market is High cost of lab testing procedure. The cost of lung cancer liquid biopsy is affordable when compared with the cost of tissue biopsy; however, the cost is still high for emerging countries. For the detection of cancerous cells in the lungs, the liquid biopsy is regarded as an emerging and a more convenient alternative to tissue biopsy, but the cost of the procedure is high, which hinders the adoption rate.

Companies Mentioned

Biocept, Exosome Diagnostics, F. Hoffmann-La Roche, and QIAGEN, AccuraGen, Agena Bioscience, BARD1, BGI, Biodesix, Bio-Rad Laboratories, Cancer Genetics, CellMax Life, Circulogene, CLEARBRIDGE BIOMEDICS, Cynvenio Biosystems, EntroGen, Epic Sciences, Epigenomics, Fluxion Biosciences, Freenome, Gencurix, Genetracer Biotech, Genomic Health, Grail, Guardant Health, HeliTec, Inivata, Lonza, MedGenome, Nanoview Diagnostics, Natera, Novogene, OncoCyte, OncoDNA, Pathway Genomics, Personal Genome Diagnostics, Predicine, Shuwen Biotech, Sysmex, Thermo Fisher Scientific, Transgenomic, and Trovagene.

  • Executive summary
  • Scope of the report
  • Research methodology
  • Introduction
    • Market outline
      • Table Overview of tissue biopsy and liquid biopsy used for detection of lung cancer
  • Market landscape
    • Market ecosystem
      • Table Parent market
    • Market segmentation analysis
      • Table Market segments
  • Market sizing
    • Market definition
    • Market sizing 2016
      • Table Market size 2016
    • Market size and forecast 2016-2021
      • Table Global lung cancer liquid biopsy market 2016-2021 ($ millions)
      • Table Global lung cancer liquid biopsy market: Year-over-year growth 2017-2021 (%)
  • Five forces analysis
    • Table Five forces analysis
  • Market segmentation by product
    • Segmentation by product
      • Table Global lung cancer liquid biopsy market by product 2016-2021 (%)
    • Comparison by product
      • Table Comparison by product
    • Global lung cancer liquid biopsy market by CTCs and ctDNA
      • Table Global lung cancer liquid biopsy market by CTCs and ctDNA: Market overview
      • Table Global lung cancer liquid biopsy market by CTCs and ctDNA 2016-2021 ($ millions)
      • Table Global lung cancer liquid biopsy market by CTCs and ctDNA: Year-over-year growth 2017-2021 (%)
    • Global lung cancer liquid biopsy market by exosomes and RNA
      • Table Global lung cancer liquid biopsy market by exosomes and RNA: Market overview
      • Table Global lung cancer liquid biopsy market by exosomes and RNA 2016-2021 ($ millions)
      • Table Global lung cancer liquid biopsy market by exosomes and RNA: Year-over-year growth 2017-2021 (%)
    • Market opportunity by product
      • Table Market opportunity by product
  • Market segmentation by end-user
    • Segmentation by end-user
    • Market share by end-user
      • Table Market share by end-user
      • Table Global lung cancer liquid biopsy market by end-users 2016: Market overview
    • Clinical diagnostic laboratories
    • Hospitals and clinics
    • Physicians' office laboratories
  • Regional landscape
    • Geographical segmentation
      • Table Global lung cancer liquid biopsy market by geography 2016-2021 (%)
    • Regional comparison
      • Table Regional comparison
    • Lung cancer liquid biopsy market in Americas
      • Table Lung cancer liquid biopsy market in Americas 2016-2021 ($ millions)
      • Table Lung cancer liquid biopsy market in Americas: Year-over-year growth 2017-2021 (%)
      • Table Top 3 countries in Americas
    • Lung cancer liquid biopsy market in EMEA
      • Table Lung cancer liquid biopsy market in EMEA 2016-2021 ($ millions)
      • Table Lung cancer liquid biopsy market in EMEA: Year-over-year growth 2017-2021 (%)
      • Table Top 3 countries in EMEA
    • Lung cancer liquid biopsy market in APAC
      • Table Lung cancer liquid biopsy market in APAC 2016-2021 ($ millions)
      • Table Lung cancer liquid biopsy market in APAC: Year-over-year growth 2017-2021 (%)
      • Table Top 3 countries in APAC
    • Market opportunity
  • Decision framework
  • Drivers and challenges
    • Market drivers
      • Table Addressable market of lung cancer 2016
    • Market challenges
      • Table Limitations associated with the application of lung cancer liquid biopsy
  • Market trends
    • Growing partnership agreements
    • Vendors' focus on clinical trials
    • Application of liquid biopsy for personalized treatment
  • Vendor landscape
    • Competitive landscape
      • Table Competitive structure analysis of global lung cancer liquid biopsy market 2016
      • Table Strategic success factors of companies in global lung cancer liquid biopsy market 2016
  • Key vendor analysis
    • Biocept
      • Table Biocept: Key highlights
      • Table Biocept: Strength assessment
      • Table Biocept: Strategy assessment
      • Table Biocept: Opportunity assessment
    • Exosome Diagnostics
      • Table Exosome Diagnostics: Key highlights
      • Table Exosome Diagnostics: Strength assessment
      • Table Exosome Diagnostics: Strategy assessment
      • Table Exosome Diagnostics: Opportunity assessment
    • F. Hoffmann-La Roche
      • Table F. Hoffmann-La Roche: Key highlights
      • Table F. Hoffmann-La Roche: Strength assessment
      • Table F. Hoffmann-La Roche: Strategy assessment
      • Table F. Hoffmann-La Roche: Opportunity assessment
    • QIAGEN
      • Table QIAGEN: Key highlights
      • Table QIAGEN: Strength assessment
      • Table QIAGEN: Strategy assessment
      • Table QIAGEN: Opportunity assessment
    • Key companies to watch
      • Table Biocartis: Company assessment
      • Table Siemens Healthcare: Company assessment
    • Other prominent vendors
      • Table Global lung cancer liquid biopsy market: Other prominent vendors
  • Appendix
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report